CSBTF logo

Kuros Biosciences AG (CSBTF) Aktienanalyse

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Mit einem Kurs von $ ist Kuros Biosciences AG (CSBTF) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 57/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.

Zuletzt analysiert: 17. März 2026
57/100 KI-Bewertung

Kuros Biosciences AG (CSBTF) Gesundheitswesen & Pipeline-Uebersicht

CEOChristopher T. Fair
Mitarbeiter122
HauptsitzSchlieren, CH
IPO-Jahr2014

Kuros Biosciences AG specializes in developing and commercializing biopharmaceutical products for tissue repair and bone regeneration, with a focus on orthobiologics and sealants. The company's pipeline targets significant unmet needs in orthopedics, spinal surgery, and neurosurgery, positioning it within the competitive biotechnology landscape.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 17. März 2026

Investmentthese

Kuros Biosciences AG presents a compelling investment thesis based on its innovative product pipeline and strategic focus on tissue repair and bone regeneration. With a market capitalization of $1.23 billion and a P/E ratio of 563.02, the company demonstrates significant growth potential. Key value drivers include the commercial success of MagnetOs products and the advancement of KUR-111 and KUR-113 through clinical trials. The company's collaboration with Checkmate Pharmaceuticals also adds potential upside. However, investors should be aware of the risks associated with clinical trial outcomes and regulatory approvals. The company's high gross margin of 87.0% indicates pricing power. The beta of 0.63 suggests lower volatility than the market.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Market capitalization of $1.23 billion reflects investor confidence in Kuros Biosciences' growth potential.
  • A P/E ratio of 563.02 indicates high expectations for future earnings growth.
  • Gross margin of 87.0% demonstrates strong pricing power and efficient cost management.
  • Beta of 0.63 suggests lower volatility compared to the broader market.
  • The company's focus on tissue repair and bone regeneration addresses a significant market need in orthopedics, spinal surgery, and neurosurgery.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Innovative product pipeline targeting unmet clinical needs.
  • Strong gross margin indicating pricing power.
  • Established presence in key markets (US and EU).
  • Strategic partnerships and collaborations.

Schwaechen

  • Reliance on successful clinical trial outcomes.
  • Dependence on regulatory approvals.
  • Limited product diversification.
  • OTC market trading may limit liquidity.

Katalysatoren

  • Upcoming: Clinical trial results for KUR-111 in tibial plateau fractures (2027-2028).
  • Upcoming: Clinical trial results for KUR-113 in tibial shaft fractures and spinal interbody fusion (2027-2028).
  • Upcoming: Regulatory approval and commercial launch of Neuroseal in the EU and US (2026-2027).
  • Ongoing: Expansion of MagnetOs product line into new geographic markets.
  • Ongoing: Strategic partnerships and collaborations to expand product pipeline.

Risiken

  • Potential: Unfavorable clinical trial results for KUR-111 and KUR-113.
  • Potential: Delays in regulatory approval for Neuroseal.
  • Potential: Competition from other biopharmaceutical companies.
  • Ongoing: Dependence on successful commercialization of existing products.
  • Ongoing: Risks associated with operating in the OTC market.

Wachstumschancen

  • Expansion of MagnetOs product line: Kuros Biosciences can expand the MagnetOs product line into new geographic markets and applications. The global orthobiologics market is projected to reach $7.9 billion by 2027, providing a significant opportunity for growth. Timeline: Ongoing.
  • Advancement of KUR-111 and KUR-113: Successful completion of clinical trials and regulatory approval for KUR-111 and KUR-113 would represent a major growth catalyst for Kuros Biosciences. These products target tibial plateau and tibial shaft fractures, respectively, addressing a significant unmet need in orthopedic surgery. Timeline: 2027-2028.
  • Commercialization of Neuroseal: The commercialization of Neuroseal, a synthetic tissue sealant for the prevention of cerebrospinal fluid leakage, represents another growth opportunity for Kuros Biosciences. The market for tissue sealants is growing, driven by increasing demand for minimally invasive surgical procedures. Timeline: 2026-2027.
  • Strategic partnerships and collaborations: Kuros Biosciences can pursue strategic partnerships and collaborations to expand its product pipeline and geographic reach. The collaboration with Checkmate Pharmaceuticals for the development of CYT003 demonstrates the company's commitment to this strategy. Timeline: Ongoing.
  • Acquisition of complementary technologies: Kuros Biosciences can acquire complementary technologies to strengthen its product portfolio and enhance its competitive position. This could include technologies related to biomaterials, drug delivery, or surgical techniques. Timeline: Opportunistic.

Chancen

  • Expansion into new geographic markets.
  • Development of new applications for existing products.
  • Acquisition of complementary technologies.
  • Increasing demand for minimally invasive surgical procedures.

Risiken

  • Competition from other biopharmaceutical companies.
  • Changes in regulatory requirements.
  • Unfavorable clinical trial results.
  • Economic downturn affecting healthcare spending.

Wettbewerbsvorteile

  • Proprietary technology and intellectual property.
  • Established distribution network in key markets.
  • Strong relationships with key opinion leaders.
  • Regulatory expertise and experience.

Ueber CSBTF

Kuros Biosciences AG, headquartered in Schlieren, Switzerland, is a biopharmaceutical company dedicated to the development and commercialization of innovative products for tissue repair and bone regeneration. The company operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. Kuros Biosciences' story began with a vision to address unmet needs in orthopedics, spinal surgery, and neurosurgery through advanced biopharmaceutical solutions. Their lead products, MagnetOs Granules and MagnetOs Putty, are designed for orthopedic, spinal, and dental applications and are available in both the EU and the US. The company's pipeline also includes fibrin/PTH orthobiologics, such as KUR-111, which has completed Phase 2b clinical trials for tibial plateau fractures, and KUR-113, which has completed Phase 2b clinical trials for tibial shaft fractures and is in Phase II trials for spinal interbody fusion. Additionally, Kuros Biosciences is developing Neuroseal EU and US, a synthetic tissue sealant aimed at preventing cerebrospinal fluid leakage following cranial or spinal surgery. Kuros Biosciences also has a collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for oncology treatments. The company's strategic focus on innovation and partnerships positions it for continued growth in the biopharmaceutical sector.

Was das Unternehmen tut

  • Develops and commercializes biopharmaceutical products.
  • Focuses on tissue repair and bone regeneration.
  • Offers orthobiologics pipeline products like MagnetOs Granules and MagnetOs Putty.
  • Develops fibrin/PTH orthobiologics such as KUR-111 and KUR-113.
  • Creates sealants pipeline products including Neuroseal EU and US.
  • Collaborates with other companies for oncology treatments.

Geschaeftsmodell

  • Develops and commercializes proprietary biopharmaceutical products.
  • Generates revenue through product sales in the US, EU, and internationally.
  • Partners with other companies for collaborative development and commercialization.
  • Focuses on high-margin products in specialized therapeutic areas.

Branchenkontext

Kuros Biosciences AG operates within the biotechnology industry, which is characterized by rapid innovation and intense competition. The market for tissue repair and bone regeneration is driven by an aging population, increasing demand for minimally invasive surgical procedures, and advancements in biomaterials. Kuros Biosciences competes with other biopharmaceutical companies developing similar products, including ASCLF (Ascentage Pharma Group Corp), CHIZF (Chiesi Farmaceutici SpA), CSPHF (CASI Pharmaceuticals Inc), MEOBF (MeoVaccs), and NPPNY (Nippon Piston Ring Co Ltd). The company's success depends on its ability to develop and commercialize innovative products that address unmet clinical needs and gain regulatory approval.

Wichtige Kunden

  • Hospitals and surgical centers.
  • Orthopedic surgeons and neurosurgeons.
  • Dental professionals.
  • Patients requiring tissue repair and bone regeneration.
KI-Zuversicht: 71% Aktualisiert: 17. März 2026

Finanzdaten

Chart & Info

Kuros Biosciences AG (CSBTF) Aktienkurs: Price data unavailable

Aktuelle Nachrichten

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CSBTF.

Kursziele

Wall-Street-Kurszielanalyse fuer CSBTF.

MoonshotScore

57/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von CSBTF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Klassifizierung

Sektor Healthcare Branche Biotechnology

Aktuelle Nachrichten

Fuehrung: Christopher T. Fair

CEO

Christopher T. Fair serves as the CEO of Kuros Biosciences AG, leading a team of 122 employees. His background includes extensive experience in the biopharmaceutical industry, with a focus on commercialization and strategic development. Prior to joining Kuros, Mr. Fair held leadership positions at various pharmaceutical companies, where he was responsible for driving revenue growth and expanding market share. He brings a wealth of knowledge in product development, regulatory affairs, and business development to Kuros Biosciences.

Erfolgsbilanz: Under Christopher T. Fair's leadership, Kuros Biosciences has focused on advancing its product pipeline and expanding its commercial presence. Key achievements include the successful commercialization of MagnetOs products and the advancement of KUR-111 and KUR-113 through clinical trials. He has also overseen the company's collaboration with Checkmate Pharmaceuticals, demonstrating his commitment to strategic partnerships.

CSBTF OTC-Marktinformationen

The OTC Other tier represents the lowest tier of the OTC market, indicating that Kuros Biosciences AG (CSBTF) may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, and investors should exercise caution due to the potential for increased risk and volatility. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may not be subject to the same level of scrutiny.

  • OTC-Stufe: OTC Other
  • Offenlegungsstatus: Unknown
Liquiditaet: Liquidity for CSBTF on the OTC market is likely limited, which can result in wider bid-ask spreads and increased trading difficulty. Lower trading volumes may make it challenging to buy or sell shares quickly without significantly impacting the price. Investors should be aware of these liquidity constraints and consider them when evaluating the potential risks and rewards of investing in CSBTF.
OTC-Risikofaktoren:
  • Limited financial disclosure increases the risk of investing in CSBTF.
  • Lower liquidity can lead to increased price volatility.
  • The OTC Other tier indicates a higher risk profile compared to companies listed on major exchanges.
  • Potential for fraud or manipulation is higher on the OTC market.
  • Lack of regulatory oversight can make it difficult to assess the company's legitimacy.
Sorgfaltspruefung-Checkliste:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the company's management team and their track record.
  • Assess the company's competitive landscape and market position.
  • Evaluate the company's product pipeline and potential for future growth.
  • Check for any legal or regulatory issues.
  • Consult with a financial advisor before investing.
  • Confirm the company's legitimacy and business operations.
Legitimitaetssignale:
  • The company has a clear business model and revenue streams.
  • Kuros Biosciences AG has an established presence in the biopharmaceutical industry.
  • The company has a pipeline of products in development.
  • The company has strategic partnerships and collaborations.
  • The company has a management team with relevant experience.

CSBTF Healthcare Aktien-FAQ

What are the key factors to evaluate for CSBTF?

Kuros Biosciences AG (CSBTF) currently holds an AI score of 57/100, indicating moderate score. Key strength: Innovative product pipeline targeting unmet clinical needs.. Primary risk to monitor: Potential: Unfavorable clinical trial results for KUR-111 and KUR-113.. This is not financial advice.

How frequently does CSBTF data refresh on this page?

CSBTF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven CSBTF's recent stock price performance?

Recent price movement in Kuros Biosciences AG (CSBTF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative product pipeline targeting unmet clinical needs.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider CSBTF overvalued or undervalued right now?

Determining whether Kuros Biosciences AG (CSBTF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying CSBTF?

Before investing in Kuros Biosciences AG (CSBTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding CSBTF to a portfolio?

Potential reasons to consider Kuros Biosciences AG (CSBTF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Innovative product pipeline targeting unmet clinical needs.. Additionally: Strong gross margin indicating pricing power.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of CSBTF?

Yes, most major brokerages offer fractional shares of Kuros Biosciences AG (CSBTF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track CSBTF's earnings and financial reports?

Kuros Biosciences AG (CSBTF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CSBTF earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • AI analysis is pending for CSBTF, so some information may be incomplete.
  • OTC market data may be less reliable than data for exchange-listed companies.
Datenquellen

Popular Stocks